

***INVESTIGATION OF THROMBOCYTE FUNCTION AND OXIDATIVE  
STRESS ON PATIENTS WITH PERIPHERAL ARTERIAL DISEASES***

***PhD Thesis***

***Maria Kurthy***

Head of the doctoral school: Prof. Dr. Sámuel Komoly  
Program leader and supervisor: Prof. Dr. Erzsébet Róth

University of Pecs Medical School  
Department of Surgical Research and Techniques  
2008

**ABBREVIATIONS:**

<b>ADP</b>	adenosine diphosphate
<b>ATP</b>	adenosine triphosphate
<b>CABG</b>	coronary artery bypass grafting
<b>CAT</b>	catalase
<b>COX</b>	cyclooxygenase
<b>DAG</b>	diacylglycerol
<b>DNA</b>	deoxyribonucleic acid
<b>DTNB</b>	5,5'-Dithio-bis(2-nitrobenzoic acid
<b>EDTA</b>	ethylenediaminetetraacetic acid
<b>GP</b>	glycoprotein
<b>GPx</b>	glutathione peroxidase
<b>GSH</b>	reduced glutathione
<b>HDL</b>	high-density lipoprotein
<b>5-HT</b>	5-hidroxi-triptamin
<b>ICAM-1</b>	intercellular adhesion molecule-1
<b>IP<sub>3</sub></b>	Inositol triphosphate or inositol 1,4,5-trisphosphate
<b>IR</b>	insulin resistance
<b>LDL</b>	low-density lipoprotein
<b>MLC</b>	myosin light chain kinase
<b>mRNA</b>	messenger RNA
<b>NO</b>	nitric oxide or nitrogen monoxide
<b>NSAID</b>	non-steroidal anti-inflammatory drug
<b>OCS</b>	open canalicular system
<b>P47</b>	pleckstrin
<b>PAD</b>	peripheral arterial disease
<b>PAF</b>	platelet activating factor
<b>PAI-1</b>	plasminogen activator inhibitor-1
<b>PDGF</b>	platelet derived growth factor
<b>PGG<sub>2</sub></b>	prostaglandin G <sub>2</sub>
<b>PGH<sub>2</sub></b>	prostaglandin H <sub>2</sub>
<b>PGI<sub>2</sub></b>	prostaglandin I <sub>2</sub>
<b>PIP<sub>2</sub></b>	phosphatidylinositol biphosphate
<b>PLA<sub>2</sub></b>	phospholipases A <sub>2</sub>
<b>TCT</b>	thrombocyte
<b>PMA</b>	phorbol 12-myristate 13-acetate
<b>PPP</b>	platelet poor plasma
<b>PRP</b>	platelet rich plasma
<b>RNS</b>	reactive nitrogen species
<b>ROS</b>	reactive oxygen species
<b>SOD</b>	superoxide dismutase
<b>T<sub>1</sub>DM</b>	type-1 diabetes mellitus
<b>T<sub>2</sub>DM</b>	type-2 diabetes mellitus
<b>TGF</b>	transforming growth factor
<b>TIA</b>	transient ischemic attack
<b>TRIS</b>	tris(hydroxymethyl)aminomethane
<b>TS</b>	thromboxane synthase
<b>TXA<sub>2</sub></b>	thromboxane A <sub>2</sub>
<b>Xox</b>	Xanthine oxidase
<b>vWF</b>	Von Willebrand factor

## **1. Introduction:**

### ***1. 1. Peripheral arterial disease and ischemia reperfusion injury***

The frequency of peripheral arterial disease (PAD) has been increased parallel with the elevation of the expected lifespan of human population. The frequency of PAD in adults above 50 years is 20 %.

There are common complex pathological backgrounds of peripheral obliterative arterial sclerosis, the coronary sclerosis, and the disease of carotis system, though PAD patients have been exposed to increased risk of cardiovascular and cerebrovascular events.

The incidence of PAD among diabetic patients is higher than in the metabolically healthy subjects. The complications of PAD accompanied by diabetes are more serious, than in non diabetic people. In spite of this comparative data of thrombocyte function and antioxidant / prooxidant status of type-1 and type-2 diabetic patients (T<sub>1</sub>DM, T<sub>2</sub>DM) with PAD are hardly found in the scientific literature.

### ***1. 2. The special feature of thrombocyte among physiological and pathological circumstances***

Thrombocytes have important roles in the maintenance of haemostasis, in the modulation of inflammation and immunity, they have bactericidal effect, they participate in wound healing, and tissue regeneration. At the same time platelets play a major role in acute ischaemic syndromes and in peripheral vascular disease. They are involved in the development and progression of atherosclerosis, native vessel and graft thrombosis. They have a central role in the development of restenosis and reocclusion after peripheral percutaneous transluminal angioplasty.

The most important inducers of platelet aggregation are thromboxaneA<sub>2</sub>, adenosine diphosphate (ADP), collagen, thrombin, 5-hydroxy-triptamin (5-HT) and adrenaline.

Several author described the increase of TXA synthesis in instable angina, which is indicative of the direct effect of spontaneous ischemia on platelet aggregation.

ADP dependent platelet aggregation is increased in stable angina while the antiaggregating effects of nitrogen monoxide (NO) donors are reduced. Smoking, coronary artery diseases, diabetes, arteriosclerosis, hypercholesterolemia has been resulting in increased aggregability of platelet.

Coronary artery diseases are more serious, if accompanied by diabetes. The endothelial layer maintains the equilibrium among prostanoid synthesising system, cyclooxygenases and prostaglandins. Inflamed endothelium induces the adhesion of platelet into the cell surface, by the increases of the expression of intercellular adhesion molecule (ICAM-1), which accompanied by the increased expression of  $\alpha_2\beta_3$  cell surface integrin in the platelet side. Several kind of inflammatory and mitogenic factors are secreted by thrombocyte into the microenvironment in the course of adhesion processes, which are able to influence the chemotactic, adhesive and proteolytic nature of endothelial cells. In pathological situations platelets can respond quickly to the changes of the endothelial cells (plack rupture, fatty streaks) and the exposition of subendothelial layers.

Thrombocytes of familiar hypercholesterolemic patients are more sensitive to platelet agonists than it can be observed in healthy people. Hypertensive and hypercholesterolemic patients have higher thrombomodulin level and their thrombin productions are increased. The proaggregatory effect of oxidised LDL cholesterol was also revealed. Summarising the literary data, it can be concluded that several diseases accompanied by hyperaggregability of platelets.

Studying the clinical picture of different vascular diseases may results in the better understanding the diseases, and can provide new opportunities to find new therapeutic targets

for the treatment. This was the reason why we began to study the thrombocyte function and antioxidant/prooxidant status of patients with peripheral arterial disease.

### ***1. 3. The biology of ischemia reperfusion injury.***

Ischemia/reperfusion injury is a relevant problem in case of thrombosis, embolisation, myocardial infarction, stroke, coronary bypass surgery, balloon angioplasty, thrombolysis, revascularization surgery of lower extremity and in every case when one segment of the vessels are excluded from the circulation, and then reopened. The vessel closure and the consecutive ischemia can be caused by arterial thrombosis (which originated from embolisation, stenotic arteriopathy or trauma), arterial spasmus, external compression, or anatomic alteration.

The tolerance of tissues to ischemia varies with the nature of the tissues and depends on the presence or absence of the collateral flow. Ischemia/reperfusion injury of skeletal muscles leads to an acute inflammation, which not only affects the nutritional territory of affected vessel, but also causes remote organ injury.

The acidosis, which occurs in the ischemic area, causes tissue injury or cell death. The remaining tissues adapted to the oxygen poor environment by changing their metabolic state from aerobic to anaerobic, but finally this strategy can lead to further tissue injury and cell death. The measure of tissue injuries are depend on the duration of hypoxia, the amount of the tissues are involved, and the systemic arterial pressure.

The restoration of the blood flow is the only way to salvage the tissue from the devastation, but it can not be made without risk, because of the accompanied volume, pressure, and metabolic stress. The main component of the pathophysiological molecular cascade is the neutrophil activation, and the resulted free radical production (reactive oxygen and nitrogen species (ROS, NOS respectively), and the elevated intracellular  $Ca^{2+}$  levels. In the early phase of reperfusion a sharp increase in the proinflammatory cytokines occurs. These factors all together threat the integrity of the organism, due to the damage of the key macromolecules (proteins, lipids and nucleic acids). The final results are the disintegration of the membranes which are responsible for the intracellular compartmentalisation, the injured ion transport, the injury of the contractile elements and the insufficient mitochondrial energy production.

## **2. The aims of the dissertation:**

***1. In the first part of our study we aimed to monitor the function of thrombocytes, the endogenous antioxidants (SOD, GSH, plasma total thiol group concentrations) and prooxidants (free radical production of white blood cells, MDA levels in red blood cell haemolysates and plasma, myeloperoxidase) levels in the perioperative period of emergency (12 patients; Acute group) and elective (10 patients; Elective group) revascularization surgery of lower limb. Similar values of 10 healthy blood donors (control group) were also considered.***

In this prospective randomised open study the thrombocyte function was measured by two different techniques, in whole blood and in platelet rich plasma.

We investigated the time dependent changes of thrombocyte function and prooxidant/antioxidant status in the perioperative phase of revascularization surgery of lower limb. The interaction of the thrombocyte and the other circulating cells were also investigated.

**2.** PAD is frequently accompanied by diabetes, hypertension, and smoking caused lung disorders, as we observed in the first row of experiments and in the scientific literature. In the second part of our studies thrombocyte function, prooxidant/ antioxidant status of type 1

and type 2 diabetic patients with PAD (T<sub>1</sub>DM; T<sub>2</sub>DM, respectively) were compared to each other (altogether 46 patients) and to the parameters of 11 healthy blood donors. The reason of our investigation was, that only a few systematic, comparative data can be found in the literature about the thrombocyte function, and oxidative stress status of T<sub>1</sub>DM; T<sub>2</sub>DM patients with PAD.

### **3. Monitoring thrombocyte function and oxidative stress markers in the course of revascularization surgery of lower limb**

#### **3.1. Patients**

Patients in the **Acute** group suffered from serious lower limb ischemia for several hours (4–6 hours) before surgery. In 8 patients the cause of ischemia was clear embolism, which was solved by Fogarty's embolectomy. The other patients had an acute arterial thrombosis at the level of femoral artery and one rupture of infrarenal aortic aneurism was also involved.

Patients of the **Elective** group were scheduled for revascularization surgery because of obliterative arterial disease with consequential ischemia at the level of superficial femoral artery, which was improved by angiographic and Doppler measurements. The surgical solutions were similar in all of these cases, with 42,8±16,3 min exclusion time.

All patients received antiplatelet therapy (at least 75 mg Aspirin) before the recruitment. Low molecular weight heparin was prescribed in the perioperative period.

All patients who were taking part in the study had been operated in the Department of General and Vascular Surgery, Baranya County Hospital in Pecs. Laboratory measurements were carried out in Department of Surgical Research and Techniques of Pecs University. The average age was 58,1 ± 7,3 years. Peripheral blood samples had been taken before, 2 and 24 hours after the surgery, as well as one week after operation.

#### **3. 2. Measurement of platelet aggregation and endogenous antioxidants and prooxidants.**

-Measurement of platelet aggregation:

Platelet aggregation in platelet rich plasma (PRP) was measured by the turbidimetric method of Born, by a four-channel aggregometer (Carat TX4 instrument, Carat Diagnostics Ltd. Budapest, Hungary). ADP (5 and 10 μM) and collagen (2 μg/ml) were used as aggregation inducers. The results were expressed as percentage of 100 % aggregation.

Platelet aggregation in whole blood was measured by two-channel impedance aggregometer (Chrono-log aggregometer, USA), according to the user's manual of the instrument. ADP (5 μM) or collagen (2 μg/ml) were used as inducers. The development of aggregation was recorded for six minutes and was expressed in Ohm.

- Measurement of prooxidants:

Free radical production of leucocytes was induced by phorbol myristate acetate (PMA) in whole blood, and was followed by luminometric method by Chrono-Log luminoaggregometer.

Malondialdehyde (MDA) levels in red blood cell hemolysate and in plasma, and myeloperoxidase (MPO) levels in plasma, were measured by standard photometric methods.

-Measurement of antioxidants:

Measurement of reduced glutathione (GSH) and plasma thiol (SH) groups:

GSH and plasma SH level were determined in anticoagulated whole blood (EDTA) by Ellman's reagent according to the photometric method of Sedlak and Lindsay.

Measurement of superoxide dismutase (SOD) activity in washed red blood cells haemolysate (RBC): The main principle of this measurement was that adrenaline is able to spontaneously transform to adrenochrome (a detectable colourful complex). This transformation can be blocked by SOD and SOD containing cells or tissues. The difference in the rate of rise of control and samples curves (obtained at 415 nm) were proportional to the SOD activity.

### **3.4. Statistics:**

The results were expressed as mean  $\pm$  SD or in percentage. The differences were calculated by paired and unpaired Student's t-test, and by one way analyses of variance. The alterations were considered significant when p values were less than 0,05.

### **3. 5. Results:**

#### **3. 5. 1. Aggregation in platelet rich plasma**

Aggregation measurement made possible to study thrombocyte function independently from the effects of other circulating cells.

Before surgery ADP induced maximal aggregation in PRP was reduced in both **Acute** and **Elective** groups compared to the **Control** group ( $p < 0.05$ ). This trend prevailed in the course of the study. The same pattern occurred in case of collagen induced aggregation, as well. This reduced agreeability at the level of thrombocytes indicated a satisfactory antiplatelet therapy.

#### **3. 5. 2. Aggregation measurement in whole blood:**

The reduced aggregation, was observed in patients groups in response to ADP and collagen compared to healthy people's PRP, had not been observed in whole blood. ADP and collagen induced aggregation in patients groups were comparable to Control group before the surgery and 2 and 24 hours after it, in whole blood. A statistically highly significant elevation appeared in Acute group in response to ADP and collagen induced aggregation, one week after the surgery, compared to elective and control groups, and to its own baseline values, as well.

#### **3.5. 3. Prooxidants:**

##### ***-PMA-induced ROS production in whole blood:***

Addition of PMA to several cell types (among others circulating blood cells, such as granulocytes, neutrophil cells, and platelets), resulted in increased ROS production due to activation of NADPH oxidase enzyme. The main sources of ROS in the blood stream are the leucocytes. White blood cell counts were moderately elevated in the two patient groups in the whole period of the study ( $p < 0.05$ ). Before surgery, ROS production was disproportionately high in the **Acute** group considering the mild elevation of leucocyte numbers, signed an extreme increase in the free radical producing capacity of the individual leucocytes in this case. This elevated amount of free radicals increased further in the course of the study, reaching a twenty- to fortyfold elevation compared to healthy **Controls** or the **Elective** group ( $p < 0.01$ ). Significant elevation was also observed in maximum free radical production in the **Elective** group at the end of the week, but it did not exceed the twofold elevation. The lag time of ROS production in the **Acute** group

was significantly shorter before surgery compared to the other two groups, and shortened further in the early reperfusion. In the **Acute** group, the slope of the free radical generation curve was steeper at each time point than in the other two groups. Significant elevation in the slope of free radical production was observed in the **Elective** group as well, one week after the surgery.

**- MDA levels in red blood cell hemolysate and in plasma**

Reactive oxygen species degrade polyunsaturated lipids; forming malondialdehyde. The production of this aldehyde is used as a biomarker to measure the level of oxidative stress in an organism. A significant elevation in MDA level was observed in the **Elective** group in the early phase of reperfusion compared to baseline level and to the **Control** ( $p < 0.05$ ). In the **Acute** group a standard low level of MDA was measured in the perioperative phase. The value was low before the surgery as well, signifying the lack of unsaturated fatty acids in the membrane. In our study plasma MDA levels increased significantly in patients groups. In the **Acute** group plasma MDA levels were higher than it was measured in **Elective** and **Control** groups ( $p < 0.05$ ). Plasma MDA level of **Elective** was higher than in **Control**, but it returned into the **Control** level one week after the surgery.

**- Myeloperoxidase (MPO)** is a hydrogen peroxide oxidoreductase, specifically found on mammalian granulocytic leucocytes, including polymorphonuclear leucocytes (PMN), basophils and eosinophils, responsible for the bacteriocidal capability of these cells. PMN activation and mediator release are partially responsible for the morbidity and mortality of revascularization of ischemic lower limb, regardless of the mode of intervention, surgical or thrombolytic.

In our cases plasma myeloperoxidase levels were higher in both patient groups at each time point compared to control. In a very new study was improved that myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. In our study MPO level in both patients groups were higher, than in **Control** group. After a transient reduction MPO level it returned to the levels were measured before the surgery in the surgery.

**3. 5. 4. Changes in endogenous antioxidants:**

**- Superoxide dismutase (SOD):**

SOD activity was lower in patients groups compared to **Control**, even before the surgery, and these low levels decreased further in the early reperfusion. In **Acute** group SOD level were lower than it was measured in **Elective** group, as well.

**- Reduced glutathione (GSH) levels and the concentration of plasma sulphydryl groups**

GSH levels in the three investigated groups were similar before the surgery in both patient groups, and decreased transiently during the early reperfusion, but it returned to the baseline by the end of the week. The concentrations of plasma -SH groups followed similar pattern.

**3. 6. Summary and conclusion:**

Restoration of the blood flow in the formerly ischemic tissues initiates several complications, involving local and systemic responses. Ischemia/reperfusion injury was

described almost 50 years before, but the correct mediation, the way of prevention or treatment is under investigation in nowadays, as well.

In the course of the ischemia reperfusion injury of lower limb, muscle changes is accompanied by a progressive microvascular damage. The inflammatory response following reperfusion vary greatly and depends on the time and severity of ischemia, as it was measured in our cases too.

To study the ischemia/reperfusion induced injury of revascularization surgery of patients with peripheral arterial diseases after acute critical limb ischemia and in the course of elective revascularization surgery were in the focus of the present study. According to our results in accordance with several other studies, the duration and severity of ischemia is proportional to the damage occurred after it. Studying thrombocyte function and antioxidant/prooxidant status of our unique patient groups, several new aspects of ischemia reperfusion injury were revealed. Peripheral artery disease is a common progressive disorder that attaches the circulation of the legs, particularly in people over 55 years, strengthening in these patients the greatly increased risk of heart attack or stroke, and of dying within a decade. Several aspects of the problem were intensively studied, but platelet function during the restoration of the circulation of ischemic lower limb was hardly investigated before.

#### **4. MONITORING THROMBOCYTE FUNCTION AND ANTIOXIDANT PROOXIDANT STATUS IN DIABETIC PERIPHERAL ARTERIAL DISEASES.**

##### **4. 1. Introduction**

Diabetes mellitus is a potent risk factor for the development of a wide spectrum of cardiovascular (CV) complications. The complex metabolic milieu accompanying diabetes alters blood rheology, the structure of arteries and disrupts the homeostatic functions of the endothelium.

Diabetes and PAD are frequently accompanied by each other. The duration of diabetes correlate well with the seriousness of the PAD. Among diabetic people oftener the infrapopliteal arterial occlusion than in the nondiabetic patients.

The presence of diabetes increases the frequency of intermittent claudication. The relative risk of amputation in diabetic population is 12,4-fold higher compared to the nondiabetic patients (95%, 10,9-14,9), and this value doubles above 65 years.

##### **4. 2. Aim of study.**

The aim of the second part of our study was to compare the thrombocyte function and antioxidant/prooxidant status of type 1, and type 2 diabetic patients with PAD.

##### **4.3. Materials and methods:**

###### *4. 3. 1. Patients*

Diabetic patients involved in this study were selected randomly from the diabetic outpatients with peripheral arterial diseases of Department of General and Vascular Surgery, Baranya County Hospital in Number of patients was 24 in T<sub>1</sub>DM, and 22 in T<sub>2</sub>DM groups. Ten healthy blood donors were involved as controls.

T<sub>1</sub>DM patients received insulin and T<sub>2</sub>DM patients received oral antidiabetic agents as antidiabetic therapy, with the exception of two patients who received insulin, as well.. All of the patients received antiplatelet agents. In T<sub>1</sub>DM group 4 patients received Syncumar as anticoagulant, and other 14 received low molecular weight heparine. In T<sub>2</sub>DM group all patients were received antiplatelet therapy, 4 patients were treated by Syncumar and 10 with low molecular weight heparine, as anticoagulant.



#### **4.4. Methods:**

The same methods were used as in 3.2.

#### **4.4. Statistics:**

The results were expressed as mean  $\pm$  SD or in percentage. The differences were calculated by paired and unpaired Student's t-test, and by one way analyses of variance. The alterations were considered significant when p values were less than 0,05.

The areas under the platelet aggregation curves were calculated in whole blood by Microcal/Origin 6.0 professional program. By means of this program linear regression analyses were made and correlation was determined the serum glucose levels of the patients and area under aggregation curves.

#### **4.5. Results**

##### **4.5.1. Clinical chemistry data**

Fasted serum glucose and triglyceride levels were higher than the normal values. The mean value of cholesterol level was within the normal range, but individually high values were measure, as well. The elevated fibrinogen levels were measured in both groups were considered as a sign of increased aggregability. The highest white blood cell counts were measured in T<sub>1</sub>DM ( $11,2 \pm 1,3 \times 10^4$  cell/ $\mu\text{l}^3$ ), which was significantly higher than in the control group ( $6,71 \pm 0,32 \times 10^4$  sejt/ $\mu\text{l}^3$ ), (p<0.01). The white blood cell count in the T<sub>2</sub>DM group was  $8,92 \pm 0,99 \times 10^4$  cell/ $\mu\text{l}^3$ .

##### **4.5.2. Thrombocyte function in PRP:**

ADP and collagen induced aggregation was significantly reduced in isolated platelets of both diabetic patients groups, compared to control group. The reduction was less pronounced in T<sub>2</sub>DM diabetic patients.

##### **4.5.3. Investigation of aggregation in whole blood**

ADP induced aggregation was higher in both patients groups, and Collagen induced aggregation was increased in T<sub>1</sub>DM patients compared to Control.

Similarly to our previous data, platelet aggregation measure in PRP reflected a satisfactory antiplatelet therapy, but in whole blood these differences can not be observed.

Our data revealed that measurement of aggregation in platelet rich plasma and in whole blood parallel is usefull for the exploration of therapeutic defect. In spite of the effectivity of antiplatelet therapy, was observed in isolated thrombocytes, the other circulating cells, such as white blood cells, can bypass in a paracrine manner the antiplated therapy, and my be induce platelet aggregation by free radicals or by their own resynthesised COX enzymes.

Significant linear correlation was improved in T<sub>1</sub>DM patients fasted serum glucose level and AUC of ADP-induced (p<0,005,  $R^2 = 0,6551$ ,  $y = 3,338x - 11,378$ ).

#### **4. 5. 4. Results of the prooxidant measurement**

##### **- PMA-induced free radical production:**

In the control group the PMA induced ROS production corrected to white blood cell counts were minimal ( $9,072 \pm 2,36 \text{ AU}/10^3$ ), but in the T<sub>1</sub>DM group a twentyfold elevation was measured in ROS production compared to control. ROS production in the T<sub>2</sub>DM group was five times higher than it was observed in Control.

#### **4. 5. 5. Results of the antioxidant measurements**

SOD and GSH levels were reduced in both diabetic groups, which is supposed to be an important determinant of the diabetes caused systemic oxidative stress. The reduction of SOD activity was independent from the type of diabetes. GSH level was reduced only in the T<sub>1</sub>DM group.

### **5. NOVEL FINDINGS:**

- 1.** Our study primarily monitored the effect of ischemia reperfusion injury on thrombocyte function and on prooxidant status in the whole hospitalization phase of emergency and elective revascularization surgery of lower limb. In the course of our study we revealed that satisfactory inhibition in the level of isolated thrombocytes does not mean definite prevention of thrombus formation, because of the modulatory role of cellular and non cellular components of the blood.
- 2.** We demonstrated a robust significant elevation in ADP and Collagen induced aggregation in whole blood one week after revascularization surgery of lower limb, in spite of the inhibited platelet aggregation was measured in PRP. This was accompanied by the low level of antioxidant enzyme and a permanent increase in ROS production. Similar phenomenon was not observed in elective patients..
- 3.** We demonstrated that the restoration of the circulation in PAD patients with serious limb ischemia did not followed by the restoration of antioxidant /prooxidant status.
- 4.** Our measures reveal significant differences in thrombocyte function of T<sub>1</sub>DM and T<sub>2</sub>DM, patients with PAD and improved that area under curves of T<sub>1</sub>DM correlate well with the serum glucose levels of these patients.
- 5.** SOD deficiency was demonstrated in our study was independent of the type of diabetes.
- 6.** PMA – induced ROS production was significantly higher in diabetic patients. It can be considered as novel finding, that free radical production of T<sub>1</sub>DM group was significantly higher than in T<sub>2</sub>DM patients.

## 8. Publications in connection with the dissertation

### 8. 1. Articles:

- 1. Kürthy M**, Mogyorósi T, Nagy K, Kukorelli T, Jednákovits A, Tálosi L, Bíró K.  
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.  
Ann N Y Acad Sci. 2002 Jun;967:482-9. **IF: 1,682**
- 2. Róth E, Jancsó G., Szántó Z., Kürthy M.**  
Endogén adaptáció a diabétesz tükrében.  
Metabolizmus 1. (3) 169-175. 2003
- 3. Arató E., Kollár L., Kürthy M., Jancsó G., Róth E., Merkli H., Pál E., Litter I.:**  
Az alsó végtagi revaszkularizációs szindrómáról.  
Érbetegségek 2004; 11: 115-121.
- 4. Arató E, Kürthy M, Jancsó G, Kasza G, Rozsos I, Merkli H, Pál E, Kollár L, Róth E.**  
The revascularisation syndrome of the lower limbs  
Perfusion 18 (5) 1-8 2005. **IF: 0.2**
- 5. Arató E, Kürthy M, Jancsó G, Sínay L, Fehér I, Kollár L, Róth E.**  
Monitoring of prooxidant-antioxidant state following limb revascularisation surgery  
Journal of Vascular Research 43 (1): 45-45 2006. **IF: 2,61**
- 6. Arató E, Kürthy M, Jancsó G, Sínay L, Kasza G, Verzar Z, Benko L, Cserepes B, Kollár L, Róth E.**  
Oxidative stress and leukocyte activation after lower limb revascularization surgery  
Magy Seb. 2006 Feb;59(1):50-7.
- 7. Lantos J, Csontos C, Kürthy M, Ferencz S, Róth E:** Monitoring of oxidative stress during treatment of burn injury.  
Eur. Surg. Res. 2007; 39(S1):81. **IF: 0,755**
- 8. Maria Kürthy, Endre Arató, Gabor Jancsó, László Sínay, Zsófia Verzar, Barbara Cserepes, János Lantos, Sándor Ferencz, Szabolcs Bertok, Andrea Ferencz, Lajos Kollár, Elisabeth Roth**  
Duration of hypoxia influences platelet function due to free radical production in revascularization surgery of lower limb  
Perfusion 2007; 20 (6) 187-194. **IF: 0,2**
- 9. Arató E, Kürthy M, Jancsó G, Sínay L, Kasza G, Menyhei G, Shafiei M, Varga Z, Bertalan A, Verzar Zs, Kollár L, Róth E**  
Az alsóvégtagi compartment szindróma kórtana és diagnosztikai lehetőségei  
Magyar Sebészet, 2007; 6: 301-306
- 10. E. Arató, G. Jancsó, L. Sínay, M. Kürthy, J. Lantos, S. Ferencz, S. Horváth, M. Shafiei, G. Kasza, Z. Verzar, L. Kollár, E. Róth, G. Wéber and G. Menyhei**  
Reperfusion injury and inflammatory responses following acute lower limb revascularization surgery  
Clinical Hemorheology and Microcirculation 2008 39. 79–85 **IF: 0,977**

**11. Sínay L, Kürthy M, Horváth S, Arató E, Shafiei M, Lantos J, Ferencz S, Bátor A, Balatonyi B, Verzár Z, Süto B, Kollár L, Wéber G, Roth E, Jancsó G.**  
Ischaemic postconditioning reduces peroxide formation, cytokine expression and leukocyte activation in reperfusion injury after abdominal aortic surgery in rat model.  
Clinical Hemorheology and Microcirculation 2008;40 (2):133-42. **IF: 0,977**

## **8. 2. Abstracts in connection with the dissertation:**

- 1. Kürthy M, Arató E, Jancsó G, Gasz B, Kollár L, Róth E**  
A thrombocyták funkciója és az antioxidáns státusz vizsgálata akut verőér elzáródást követően.  
Érbetegségek S1. 2005. 5.
- 2. Kürthy M, Arató E, Jancsó G, Lantos J, Fehér I., Kollár L, Róth E.**  
Egyes és kettestípusú diabéteszes perifériás érbetegek trombocita funkciója és szabadgyök termelése; in vitro inzulin hatása  
Cardiologia Hungarica 35 Supplementum A. A23.
- 3. Kürthy M, Arató E, Jancsó G, Lantos J, Fehér I, Ferencz A, Róth E:**  
Thrombocyte function and free radical production of type 1 and type 2 diabetic patients; the effect of insulin in vitro  
Diabetologia 48. Supplement 1. A 411 2005. **IF: 5.337**
- 5. Kürthy M, Arató E, Jancsó G, Lantos J, Ferencz A, Fehér I, Róth E, Kollár L**  
In vitro inzulin hatása 1-es és 2-es típusú, perifériás érszövődéssel komplikált diabéteszes betegek trombocita funkciójára és szabadgyök termelésére.  
Érbetegségek 2005. Suppl. 2. 39.
- 6. Kürthy M, Arató E, Jancsó G, Lantos J, Cserepes B, Ferencz S, Roth E.**  
Thrombocyte function following revascularisation surgery of lower limb  
Eur. Surg Res. 38. S(1) (P41) 131. **IF: 0,706**
- 7. Kürthy M, Arató E, Jancsó G, Lantos J, Cserepes B, Ferencz S, Sínay L, Róth E.**  
Thrombocyte function in the perioperative phase of acute and elective peripheral revascularisation surgery  
Experimental and Clinical Cardiology 11. (3) A35. 256. 2006.
- 8. Kürthy Mária, Dr Arató Endre, Dr Jancsó Gábor, Dr Lantos János, Dr Ferencz Sándor, Dr Bertók Szabolcs, Dr Ferencz Andrea, Dr Cserepes Barbara, Dr Horváth Szabolcs, Prof Dr Kollár Lajos, Prof Dr Róth Erzsébet**  
Az antioxidáns –prooxidáns státusz és a trombocita funkció monitorozása alsóvégtagi revaszkularizációs műtétek során.  
Érbetegségek S1, 7. 2007.
- 9. Maria Kurthy, Endre Arató, Gábor Jancsó, Barbara Cserepes, János Lantos, Sándor Ferencz, Szabolcs Bertók, Andrea Ferencz, Erzsébet Roth**  
Thrombocyte function and oxidative stress markers in blood of type 1 and type 2 diabetic patients and healthy subjects: the in vitro effects of insulin  
Diabetologia 50. S1 S298. 2007. **IF: 5,337**

- 10.** Arató E, **Kürthy M**, Jancsó G, Kasza G, Sinay L, Fehér I, Kollár L, Róth E.  
Az antioxidáns prooxidáns státusz változása akut alsó végtagi revaszkularizációs műtéteket követően.  
Magyar Sebészet 58. 279. 2005.
- 11.** **M Kürthy**, E. Arato, G. Jancso, J. Lantos, S. Ferencz, E. Bojtor, L. Sinay, L. Koller, E. Roth  
Oxidative stress markers and thrombocyte function in type -1 and type-2 diabetic patients and in vitro effects of insulin  
Journal of Vascular Research 45 (Suppl. 2) 85. 2008. **IF: 2,46**
- 12.** Rozsos I, Sinay L, Kasza G, Litter I, **Kürthy M**, Weisdorn R, Róth E, Kollár L  
A diabetic foot szindrómás betegek hemorheológiai nyomomkövetése  
Érbetegségek Suppl. 2. 38.2005.
- 13.** Arató E, **Kürthy M**, Jancsó G, Kasza G, Sinay L, Rozsos I, Kollár L, Róth E  
Az oxidatív stressz szerepe az alsóvégtagi revaszkularizációs szindrómában  
Érbetegségek 2005. Suppl. 2. 39.
- 14.** Lantos J, Csontos C, Kürthy M, Füredi R, Róth E.  
The time course of leucocyte activation markers after burn injury.  
Eur. Surg. Res. 38. S(1) (P45) 134 **IF: 0,706**
- 15.** Dr Sinay László, Dr Arató Endre, Dr Kasza Gábor, Dr Jancsó Gábor, **Kürthy Mária**, Dr Bertalan Andrea, Dr Verzár Zsófia, Prof. Dr Kollár Lajos  
Mikrocirkuláció megítélése compartment szindrómában rekesznyomás mérésével és szöveti oxigénszaturáció meghatározásával.  
Érbetegségek S1, 7. 2007.
- 16.** Dr Ferencz Sándor, **Kürthy Mária**, Dr Bertók Szabolcs, Dr Horváth Szabolcs, Prof Dr Róth Erzsébet, Prof Dr Wéber György  
Érbetegségek progressziójának követése: trombocita aggregáció, szabadgyök termelés és antioxidáns enzimek kapacitásának mérése alsóvégtag amputált betegeknél.  
Érbetegségek S1, 7. 2007.
- 17.** Dr István Miklós, **Kürthy Mária**, Dr Lantos János, Dr Róth Erzsébet  
Klinikai adatok, trombocitafunkciós vizsgálatok, valamint antioxidáns státusz elemzése orális antikoaguláns terápiában részesülő betegeknél. Érbetegségek S1, 7. 2007.
- 18.** Dr Lantos János, Dr Csontos Csaba, Dr Mühl Diana, **Kürthy Mária**, Dr Ferencs Sándor, Dr Róth Erzsébet  
Fehérvérsejtek szabadgyök-termelésének és adhéziós molekula kifejeződésének vizsgálata égett és szeptikus betegeknél. Érbetegségek S1, 7. 2007.
- 19.** Sinay L, Arató E, Horváth Sz, **Kürthy M**, Bátor A, Németh G, Balatonyi B, Róth E, Kollár L, Jancsó G. Hasi aorta okklúziót követő korai intermittáló reperfüzió hatása a reperfüziós károsodásra kísérletes és klinikai modellen. Érbetegségek, 2007/Suppl 2; 16
- 20.** Arató E, Sinay L, Kasza G, M Shafiei, Varga Z, Kollár L, **Kürthy M**, Jancsó G, Róth E.  
Alsóvégtagi rekonstruktív érműtétek során adott E-vitamin hatása a reperfüziós károsodásokra.

Érbetegségek, 2007/Suppl 2; 24

**21.** E.Arato, L. Sinay, **M. Kürthy**, G. Kasza, G weber, L. Kollar, E. Roth,  
Leukocyte activation and redox changes following aorto-biphemoral bypass surgery  
57th European Society for Cardiovascular Surgery Barcelona, Spain, April. 24-27. 2008.  
Interactive Cardio Vascular and Thoracic Surgery 7 (1) 2008.

**22.** J. Lantos, Cs Csontos, D Muhl, V. Foldi, S. Szentes, L. Bogar, **M. Kürthy**, G. Weber, E.  
Roth  
Comparative study of phagocyte function in critically ill patients: respiratory burst and  
adhesion molecule expression  
Journal of Vascular Research 45 (supplement 2) 96. 2008. **IF: 2,63**

Impact factors of full article in connection with the dissertation: **7,39**

Impact factors of the abstracts: **17,18**

**Cumulative IF: 25,57**